315 related articles for article (PubMed ID: 33651321)
1. SEOM clinical guideline for the management of cutaneous melanoma (2020).
Majem M; Manzano JL; Marquez-Rodas I; Mujika K; Muñoz-Couselo E; Pérez-Ruiz E; de la Cruz-Merino L; Espinosa E; Gonzalez-Cao M; Berrocal A
Clin Transl Oncol; 2021 May; 23(5):948-960. PubMed ID: 33651321
[TBL] [Abstract][Full Text] [Related]
2. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
3. [Guidelines for stage I to III melanoma].
Guillot B; Dalac S; Denis M; Dupuy A; Emile JF; De La Fouchardiere A; Hindie E; Jouary T; Lassau N; Mirabel X; Piperno Neumann S; De Raucourt S; Vanwijck R
Bull Cancer; 2016 Sep; 103(9):743-52. PubMed ID: 27456259
[No Abstract] [Full Text] [Related]
4. Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma.
Berrocal A; Espinosa E; Marín S; Malvehy J; Moreno D; Lozano MD; Martin-Algarra S; Lopez JA; Conill C; Rodriguez-Peralto JL
Eur J Dermatol; 2015; 25(5):392-403. PubMed ID: 26693633
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
6. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
[TBL] [Abstract][Full Text] [Related]
8. Considering adjuvant therapy for stage II melanoma.
Poklepovic AS; Luke JJ
Cancer; 2020 Mar; 126(6):1166-1174. PubMed ID: 31869447
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.
Garbe C; Peris K; Hauschild A; Saiag P; Middleton M; Bastholt L; Grob JJ; Malvehy J; Newton-Bishop J; Stratigos AJ; Pehamberger H; Eggermont AM; ; ;
Eur J Cancer; 2016 Aug; 63():201-17. PubMed ID: 27367293
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic manual of malignant melanoma].
Moroi Y
Fukuoka Igaku Zasshi; 2009 Feb; 100(2):51-8. PubMed ID: 19455975
[No Abstract] [Full Text] [Related]
11. SEOM guidelines for the management of Malignant Melanoma 2015.
Berrocal A; Arance A; Espinosa E; Castaño AG; Cao MG; Larriba JL; Martín JA; Márquez I; Soria A; Algarra SM
Clin Transl Oncol; 2015 Dec; 17(12):1030-5. PubMed ID: 26669314
[TBL] [Abstract][Full Text] [Related]
12. Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis.
Gonzalez A
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):24-30. PubMed ID: 30374897
[TBL] [Abstract][Full Text] [Related]
13. Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.
Dalle S; Varey E; Nguyen JM; Dupuy A; Montaudie H; Lesage C; Mortier L; Leccia MT; Skowron F; Celerier P; Meyer N; Dutriaux C; Dalac-Rat S; Khammari A; Lebbe C; Dréno B
Eur J Dermatol; 2020 Aug; 30(4):389-396. PubMed ID: 32815816
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapies in the treatment of stage II and III malignant melanoma.
Kavanagh D; Hill AD; Djikstra B; Kennelly R; McDermott EM; O'Higgins NJ
Surgeon; 2005 Aug; 3(4):245-56. PubMed ID: 16121769
[TBL] [Abstract][Full Text] [Related]
15. Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.
Chapman PB; Hauschild A; Sondak VK
Am Soc Clin Oncol Educ Book; 2014; ():e412-21. PubMed ID: 24857132
[TBL] [Abstract][Full Text] [Related]
16. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma".
Pflugfelder A; Kochs C; Blum A; Capellaro M; Czeschik C; Dettenborn T; Dill D; Dippel E; Eigentler T; Feyer P; Follmann M; Frerich B; Ganten MK; Gärtner J; Gutzmer R; Hassel J; Hauschild A; Hohenberger P; Hübner J; Kaatz M; Kleeberg UR; Kölbl O; Kortmann RD; Krause-Bergmann A; Kurschat P; Leiter U; Link H; Loquai C; Löser C; Mackensen A; Meier F; Mohr P; Möhrle M; Nashan D; Reske S; Rose C; Sander C; Satzger I; Schiller M; Schlemmer HP; Strittmatter G; Sunderkötter C; Swoboda L; Trefzer U; Voltz R; Vordermark D; Weichenthal M; Werner A; Wesselmann S; Weyergraf AJ; Wick W; Garbe C; Schadendorf D; ;
J Dtsch Dermatol Ges; 2013 Aug; 11 Suppl 6():1-116, 1-126. PubMed ID: 24028775
[TBL] [Abstract][Full Text] [Related]
17. Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma.
Ziogas DC; Diamantopoulos P; Benopoulou O; Anastasopoulou A; Bafaloukos D; Stratigos AJ; Kirkwood JM; Gogas H
Oncologist; 2020 Aug; 25(8):e1209-e1220. PubMed ID: 32271498
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Melanoma.
Glitza Oliva IC; Alqusairi R
Adv Exp Med Biol; 2018; 995():43-63. PubMed ID: 30539505
[TBL] [Abstract][Full Text] [Related]
19. Exclusion criteria vs reality: dual BRAF/MEK inhibition and radiotherapy in a patient with melanoma metastatic to the brain and ECOG 3.
Márquez-Rodas I; Avilés-Izquierdo JA; Parra V; Álvarez-González A; Borrego P; Fernández-García P; Guzmán-de-Villoria JA; Jerez Y; Martin M
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 26350195
[TBL] [Abstract][Full Text] [Related]
20. The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.
Rulli E; Legramandi L; Salvati L; Mandala M
Cancer; 2019 Nov; 125(21):3776-3789. PubMed ID: 31287564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
